ArticlePharmaceutics2022
In Vivo Evaluation of a Gastro-Resistant HPMC-Based "Next Generation Enteric" Capsule.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- In vivo comparison of enteric capsule shells composed of different HPMCAS grades after simultaneous intake by dual MRI labeling and pharmacokinetics.International journal of pharmaceutics: X · 2026Article
- Evaluation of Targeted-Release Capsule Formulations for Protection of the Acid-Sensitive Enzyme Pancreatin Under Fasted and Fed Intestinal Conditions In Vitro.Pharmaceutics · 2026Article
- Profiling the human luminal small intestinal microbiome using a novel ingestible medical device.medRxiv : the preprint server for health sciences · 2025Article
- Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging.Molecular pharmaceutics · 2025Article
- Exploring the human small intestinal luminal microbiome via a newly developed ingestible sampling device.ISME communications · 2025Article
- Enteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum.Molecular pharmaceutics · 2024Article
- Use of Magnetic Resonance Imaging for Visualization of Oral Dosage Forms in the Human Stomach: A Scoping Review.Molecular pharmaceutics · 2024Article
- Pilot Study: Safety and Performance Validation of an Ingestible Medical Device for Collecting Small Intestinal Liquid in Healthy Volunteers.Methods and protocols · 2024Article
- Flexible Coatings Facilitate pH-Targeted Drug Release via Self-Unfolding Foils: Applications for Oral Drug Delivery.Pharmaceutics · 2024Article
- In Vivo Evaluation of a Gastro-Resistant EnprotectPharmaceutics · 2023Article
- Drying Process of HPMC-Based Hard Capsules: Visual Experiment and Mathematical Modeling.Gels (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach. However, an enteric formulation is often accompanied with a higher development effort in the first place and the potential degradation of fragile APIs during the coating process. Ready-to-use enteric hard capsules would be an easily available alternative to test and develop APIs in enteric formulations, while decreasing the time and cost of process development. In this regard, Lonza Capsugel
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.